Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies
Open Access
- 22 February 2019
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 102 (6) , 447-456
Abstract
Objective: Despite long‐standing safe and effective use of immunoglobulin replacement therapy (IgRT) in primary immunodeficiency, clinical data on IgRT in patients with secondary immunodeficiency (SID) due to B‐cell lymphoproliferative diseases are limited. Here, we examine the correlation between approved IgRT indications, treatment recommendations, and clinical practice in SID.Methods: An international online survey of 230 physicians responsible for the diagnosis of SID and the prescription of IgRT in patients with hematological malignancies was conducted.Results: Serum immunoglobulin was measured in 83% of patients with multiple myeloma, 76% with chronic lymphocytic leukemia, and 69% with non‐Hodgkin lymphoma. Most physicians (85%) prescribed IgRT after ≥2 severe infections. In Italy, Germany, Spain, and the United States, immunoglobulin use was above average in patients with hypogammaglobulinemia, while in the UK considerably fewer patients received IgRT. The use of subcutaneous immunoglobulin was highest in France (34%) and lowest in Spain (19%). Immunologists measured specific antibody responses, performed test immunization, implemented IgRT, and used subcutaneous immunoglobulin more frequently than physicians overall.Conclusions: The management of SID in hematological malignancies varied regionally. Clinical practice did not reflect treatment guidelines, highlighting the need for robust clinical studies on IgRT in this population and harmonization between countries and disciplines.Keywords
Funding Information
- Octapharma
This publication has 27 references indexed in Scilit:
- Update on the use of immunoglobulin in human disease: A review of evidenceJournal of Allergy and Clinical Immunology, 2017
- Immunoglobulin Replacement Therapy in Secondary HypogammaglobulinemiaFrontiers in Immunology, 2014
- Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patientsHaematologica, 2014
- Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patientsHaematologica, 2014
- Antibody Deficiency Secondary to Chronic Lymphocytic Leukemia: Should Patients be Treated with Prophylactic Replacement Immunoglobulin?Journal of Clinical Immunology, 2014
- Home-Based Subcutaneous Immunoglobulin Versus Hospital-Based Intravenous Immunoglobulin in Treatment of Primary Antibody Deficiencies: Systematic Review and Meta AnalysisJournal of Clinical Immunology, 2012
- Subcutaneous Administration of IgGImmunology and Allergy Clinics of North America, 2008
- Guidelines on the Use of Intravenous Immune Globulin for Hematologic ConditionsTransfusion Medicine Reviews, 2007
- Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimesBritish Journal of Haematology, 1994
- Intravenous Immunoglobulin for the Prevention of Infection in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 1988